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Image in Focus
Pictures courtesy of Dr. Luiz Alberto Benvenuti
Figure. A and B - Gross examination of the heart. A - Opened right cardiac chambers. The asterisk marks the atrial septal defect 
located at the fossa ovalis (so-called secundum defect); B - The right ventricle hypertrophy and pulmonary artery trunk (PT) dilation 
with atherosclerotic plaques; C and D - Macroscopic findings of the lungs; C - The dilation and atherosclerosis of the pulmonary 
artery (PA) (arrowhead points to a plaque) and its branches; D - PA thrombosis (white arrowhead). TV = tricuspid valve.
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Eisenmenger syndrome (ES) stands for pulmonary 
hypertension, reversal of the central shunt’s flow, 
and cyanosis secondary to any congenital heart 
defect (CHD) associated with non-repaired intra- or 
extra-cardiac communication.1 In this syndrome, the 
original central left-to-right shunt reverses the direction 
to right-to-left due to long-standing pulmonary 
hypertension and high pulmonary vascular resistance 
turning to systemic or supra-systemic levels, and due 
to structural obstructive pulmonary vascular disease.
In 1897, the Austrian doctor, Victor Eisenmenger 
(1864-1932), firstly described this syndrome in the 
article entitled “The congenital ventricular septal 
defects of the heart” published in the German medical 
journal Zeitschrifft für Klinische Medizin,2 reporting 
the case of a 32-year-old man with clubbing fingers, 
cyanosis since infancy, the presence of a systolic 
murmur and a pronounced second heart sound. 
Over the patient’s last 3 years of life, he began 
presenting dyspnea, which evolved to heart failure, 
and he died due to a massive hemoptysis. At the 
autopsy, pulmonary hemorrhage was confirmed along 
with a ventricular septal defect, a right ventricular 
hypertrophy accompanied by an overriding aorta and 
atheromatosis of the major pulmonary arteries. In the 
years since Eisenmenger’s descriptions were published, 
they were better understood and became appropriate 
to the practice of cardiology. The name of Doctor 
Eisenmenger is eponymously attached to this entity. 
However, at the time the first case was reported, neither 
pulmonary hypertension nor pulmonary arteriolar 
disease were known.3,4 The pulmonary hypertension 
and the increase in the pulmonary vascular resistance 
associated with ES were not described until the 1950s.
The chronic pulmonary overf low and the 
transmission of high systemic pressure to the pulmonary 
circulation secondary to the central left-to-right 
shunt induced, over time, the pulmonary vascular 
change characterized by the decrease of the overall 
cross-sectional area of the pulmonary arteriolar bed. 
This pulmonary vascular physical injury may cause 
mechanical stretch and intimal tears accompanied by 
histological changes with increased intrinsic elastase 
production and vascular endothelial growth factors, 
which will further give rise to intimal hyperplasia 
and medial hypertrophy of peripheral pulmonary 
arteries. Moreover, endothelial dysfunction, platelet 
activation, and increased thromboxane and endothelin 
levels will cause obstructive pulmonary lesions 
and pulmonary hypertension.5-8 Eventually, typical 
atherosclerotic lesions develop in the pulmonary 
arteries. However, the pulmonary resistance will 
show clinical significance only when two-thirds of 
the pulmonary vascular bed is compromised.9 At this 
point, those patients who still do not present oxygen 
desaturation become cyanotic, signaling the reversal 
of the central shunt. The progressive hypoxemia and 
central cyanosis of the adult patient with ES will result 
in reduced quality of life and premature death due 
to multi-systemic abnormalities, such as coagulation 
disorders, heart failure, renal insufficiency, and 
hypertrophic osteoarthropathy.9
Factors influencing the development of advanced 
pulmonary vasculopathy in subjects with atrial septal 
defect have not been completely explored. In adults, 
the general belief (though not proved) is that long 
exposure to altered flow conditions, which is largely 
dependent on right ventricular compliance, could 
alter pulmonary vascular cell biology via shear and 
stretch forces. However, ES features may be present in 
young adults with pre-tricuspid defects. Furthermore, 
advanced pulmonary vascular disease may be seen in 
young infants with no previous features of pulmonary 
overcirculation.10
Thus, the development of ES depends on the 
heart defect, its size and location (higher prevalence 
in post-tricuspid defects), and to factors that remain 
to be determined.9
The population of adults with congenital heart 
disease (known under the acronym of GUCH: grown-up 
congenital heart disease) is growing at an acceleration 
rate of 5% per year. In the USA, more than 1 million 
adults have CHD. 10% of the cases present pulmonary 
hypertension, 30% of them due to unrepaired defects. 
ES will develop in half of these patients with unrepaired 
cardiovascular defects.11 Although less frequent, large 
atrial septal defects will cause pulmonary hypertension 
during the second or third decade of life. These patients 
present a long asymptomatic period with an adjusted 
lower exercise capacity until adolescence or early 
adulthood. Gradually, exercise intolerance, cyanosis, 
exertion dyspnea, syncope, chest pain, heart failure, 
hyperviscosity syndrome (secondary to erythrocytosis), 
and rhythm disturbances (particularly atrial fibrillation) 
supervene.9 Hemoptysis is a common presentation of 
ES, which can be due to pulmonary embolism and 
infarction, rupture of the dilated pulmonary artery or 
thin pulmonary arteriole, coagulation disturbances, or 
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thrombocytopenia. Although long-term survival has 
been reported, patients with ES usually die between 
30 and 35 years old.1
Physical examination of a patient with ES will show 
cyanosis, clubbing fingers, and parasternal lift from 
right ventricle hypertrophy. Plus, a tactual closure of 
the pulmonary valve may be felt. In the case of ES due 
to atrial septal defect, the widely and fixed split of the 
S2 is invariably present, and a tricuspid regurgitation 
murmur may be audible. There will be signs of right 
heart failure as hepatomegaly, and a third heart sound 
may be present.
The Figure shows macroscopic lesions typical of 
ES, from a 56-year-old male patient with a non-repaired 
atrial septal defect. Right ventricle dilation and large 
atrial septal defect measuring 3.5 × 3.0 cm can be 
seen, as well as a prominent right ventricle, dilation 
and severe atherosclerosis of the pulmonary artery, 
prominent dilation and atherosclerosis of the right 
pulmonary artery and parenchymal branches, and 
partial thrombosis of the right pulmonary artery.
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